Imunon (IMNN) executive chair granted 4,629 shares in lieu of cash pay
Rhea-AI Filing Summary
Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. executive chairman Michael H. Tardugno reported a compensation-related stock grant rather than an open-market trade. He received 4,629 shares of Common Stock at $1.82 per share, granted in lieu of cash for base salary, bringing his direct holdings to 17,467 shares. A separate line shows 4,622 shares of Common Stock held indirectly through an IRA, reflecting existing indirect ownership rather than a new market transaction.
Positive
- None.
Negative
- None.
Insights
Routine equity compensation grant replaces part of cash salary.
The filing shows Imunon’s executive chairman receiving 4,629 shares of Common Stock at $1.82 per share as a grant or award. A footnote states this stock was granted in lieu of cash for base salary, indicating a compensation choice rather than a market trade.
Because the transaction uses code A and is classified as a grant/award acquisition, it reflects standard equity-based pay. After the grant, direct ownership rises to 17,467 shares, while an additional 4,622 shares are held indirectly in an IRA. No derivative exercises or sales appear in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 4,629 | $1.82 | $8K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. Stock granted in lieu of cash for base salary
Key Figures
Key Terms
Grant, award, or other acquisition financial
Held by IRA financial
Common Stock financial
base salary financial
FAQ
What insider transaction did Imunon (IMNN) report for Michael H. Tardugno?
Was the Imunon (IMNN) Form 4 transaction a stock purchase or sale?
What does the $1.82 price on the Imunon (IMNN) Form 4 represent?
How is the Imunon (IMNN) executive’s IRA reported in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.